Download PDF
Clin Colon Rectal Surg 2017; 30(05): 377-382
DOI: 10.1055/s-0037-1606115
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Neoadjuvant Treatment Strategies: Advanced Radiation Alternatives

Bruce D. Minsky
1   Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas
› Author Affiliations
Further Information

Publication History

Publication Date:
27 November 2017 (online)

    Permissions and Reprints

Abstract

Long-course chemoradiation therapy (CRT) has been the standard approach for locally advanced rectal tumors. Neoadjuvant CRT is associated to improved local disease control, with less toxicity when compared with adjuvant CRT, as well as the chance for pathologic complete response. The CRT regimens have improved over the past years. This article will examine selected controversies, including novel chemoradiation regimens, duration of radiation (short vs. long course), and radiation techniques such as intensity-modulated radiation therapy (IMRT).

Keywords

rectal cancer - chemoradiation therapy - short course - long course - IMRT
 

  • References

  • 1 Rödel C, Liersch T, Becker H. , et al; German Rectal Cancer Study Group. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012; 13 (07) 679-687
    CrossrefPubMedGoogle Scholar
  • 2 Rödel C, Graeven U, Fietkau R. , et al; German Rectal Cancer Study Group. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2015; 16 (08) 979-989
    CrossrefPubMedGoogle Scholar
  • 3 Aschele C, Cionini L, Lonardi S. , et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011; 29 (20) 2773-2780
    CrossrefPubMedGoogle Scholar
  • 4 Gérard JP, Azria D, Gourgou-Bourgade S. , et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010; 28 (10) 1638-1644
    CrossrefPubMedGoogle Scholar
  • 5 Gérard JP, Azria D, Gourgou-Bourgade S. , et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 2012; 30 (36) 4558-4565
    CrossrefPubMedGoogle Scholar
  • 6 O'Connell MJ, Colangelo LH, Beart RW. , et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol 2014; 32 (18) 1927-1934
    CrossrefPubMedGoogle Scholar
  • 7 Jung M, Shin SJ, Koom WS. , et al. A randomized phase 2 study of neoadjuvant chemoradiation therapy with 5-fluorouracil/leucovorin or irinotecan/S-1 in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2015; 93 (05) 1015-1022
    CrossrefPubMedGoogle Scholar
  • 8 Matsusaka S, Ishihara S, Kondo K. , et al. A multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (SHOGUN trial). Radiother Oncol 2015; 116 (02) 209-213
    CrossrefPubMedGoogle Scholar
  • 9 Beppu N, Matsubara N, Kakuno A. , et al. Feasibility of modified short-course radiotherapy combined with a chemoradiosensitizer for T3 rectal cancer. Dis Colon Rectum 2015; 58 (05) 479-487
    CrossrefPubMedGoogle Scholar
  • 10 Buijsen J, van den Bogaard J, Jutten B. , et al. A phase I-II study on the combination of rapamycin and short course radiotherapy in rectal cancer. Radiother Oncol 2015; 116 (02) 214-220
    CrossrefPubMedGoogle Scholar
  • 11 Willett CG, Duda DG, di Tomaso E. , et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009; 27 (18) 3020-3026
    CrossrefPubMedGoogle Scholar
  • 12 van Cutsem E, Lang I, D'haens G. , et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 2008; 26 (15 suppl): 2
    CrossrefPubMedGoogle Scholar
  • 13 Campbell PT, Newton CC, Dehal AN, Jacobs EJ, Patel AV, Gapstur SM. Impact of body mass index on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol 2012; 30 (01) 42-52
    PubMedGoogle Scholar
  • 14 Resch G, De Vries A, Öfner D. , et al; Austrian Breast and Colorectal Cancer Study Group. Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer--a two stage phase II clinical trial. Radiother Oncol 2012; 102 (01) 10-13
    CrossrefPubMedGoogle Scholar
  • 15 Das P, Lin EH, Bhatia S. , et al. Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys 2006; 66 (05) 1378-1383
    CrossrefPubMedGoogle Scholar
  • 16 Chung KY, Minsky B, Schrag D. , et al. Phase I trial of preoperative cetuximab with concurrent contiuous infusion 5-fluorouracil and pelvic radiation in patients with local-regionally advanced rectal cancer. J Clin Oncol 2006; 24 (18 suppl) 3560
    PubMedGoogle Scholar
  • 17 Rödel C, Arnold D, Hipp M. , et al. Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys 2008; 70 (04) 1081-1086
    CrossrefPubMedGoogle Scholar
  • 18 Dewdney A, Cunningham D, Tabernero J. , et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol 2012; 30 (14) 1620-1627
    CrossrefPubMedGoogle Scholar
  • 19 Sclafani F, Gonzalez D, Cunningham D. , et al. TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial. J Natl Cancer Inst 2014; 106 (07) 1-4
    CrossrefPubMedGoogle Scholar
  • 20 Sclafani F, Chau I, Cunningham D. , et al. Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial. Ann Oncol 2015; 26 (09) 1936-1941
    CrossrefPubMedGoogle Scholar
  • 21 Sclafani F, Peckitt C, Cunningham D. , et al. Short- and long-term quality of life and bowel function in patients with MRI-defined, high-risk, locally advanced rectal cancer treated with an intensified neoadjuvant strategy in the randomized phase 2 EXPERT-C trial. Int J Radiat Oncol Biol Phys 2015; 93 (02) 303-312
    CrossrefPubMedGoogle Scholar
  • 22 Helbling D, Bodoky G, Gautschi O. , et al. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. Ann Oncol 2013; 24 (03) 718-725
    CrossrefPubMedGoogle Scholar
  • 23 Mohiuddin M, Paulus R, Mitchell E. , et al. Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer. Int J Radiat Oncol Biol Phys 2013; 86 (03) 523-528
    CrossrefPubMedGoogle Scholar
  • 24 Wong SJ, Winter K, Meropol NJ. , et al. Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2012; 82 (04) 1367-1375
    CrossrefPubMedGoogle Scholar
  • 25 Kapiteijn E, Marijnen CA, Nagtegaal ID. , et al; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345 (09) 638-646
    CrossrefPubMedGoogle Scholar
  • 26 van Gijn W, Marijnen CA, Nagtegaal ID. , et al; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011; 12 (06) 575-582
    CrossrefPubMedGoogle Scholar
  • 27 Sauer R, Becker H, Hohenberger P. , et al. Preoperative chemoradiotherapy as compared with postoperative chemoradiotherapy for locally advanced rectal cancer. N Engl J Med 2004; 351: 11-20
    CrossrefPubMedGoogle Scholar
  • 28 Sauer R, Liersch T, Merkel S. , et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012; 30 (16) 1926-1933
    CrossrefPubMedGoogle Scholar
  • 29 Stephens RJ, Thompson LC, Quirke P. , et al. Impact of short-course preoperative radiotherapy for rectal cancer on patients' quality of life: data from the Medical Research Council CR07/National Cancer Institute of Canada Clinical Trials Group C016 randomized clinical trial. J Clin Oncol 2010; 28 (27) 4233-4239
    CrossrefPubMedGoogle Scholar
  • 30 Pettersson D, Lörinc E, Holm T. , et al. Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer. Br J Surg 2015; 102 (08) 972-978 ; discussion 978
    CrossrefPubMedGoogle Scholar
  • 31 Pettersson D, Glimelius B, Iversen H, Johansson H, Holm T, Martling A. Impaired postoperative leucocyte counts after preoperative radiotherapy for rectal cancer in the Stockholm III Trial. Br J Surg 2013; 100 (07) 969-975
    CrossrefPubMedGoogle Scholar
  • 32 Yeo SG, Oh JH, Kim DY. , et al. Preoperative short-course concurrent chemoradiation therapy followed by delayed surgery for locally advanced rectal cancer: a phase 2 multicenter study (KROG 10-01). Int J Radiat Oncol Biol Phys 2013; 86 (01) 34-39
    CrossrefPubMedGoogle Scholar
  • 33 Garcia-Aguilar J, Smith DD, Avila K, Bergsland EK, Chu P, Krieg RM. ; Timing of Rectal Cancer Response to Chemoradiation Consortium. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg 2011; 254 (01) 97-102
    CrossrefPubMedGoogle Scholar
  • 34 van Dijk TH, Tamas K, Beukema JC. , et al. Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer. Ann Oncol 2013; 24 (07) 1762-1769
    CrossrefPubMedGoogle Scholar
  • 35 Myerson RJ, Tan B, Hunt S. , et al. Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer. Int J Radiat Oncol Biol Phys 2014; 88 (04) 829-836
    CrossrefPubMedGoogle Scholar
  • 36 Bujko K, Nowacki MP, Nasierowska-Guttmejer A. , et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. . Radiother Oncol 2004; 72 (01) 15-24
    CrossrefPubMedGoogle Scholar
  • 37 Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006; 93 (10) 1215-1223
    CrossrefPubMedGoogle Scholar
  • 38 Bujko K. Neoadjuvant chemoradiation for fixed cT3 or cT4 rectal cancer: results of a Polish II multicenter phase III study. J Clin Oncol 2016; 34 (4 Supp): 489
    PubMedGoogle Scholar
  • 39 Ngan SY, Burmeister B, Fisher RJ. , et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 2012; 30 (31) 3827-3833
    CrossrefPubMedGoogle Scholar
  • 40 Samuelian JM, Callister MD, Ashman JB, Young-Fadok TM, Borad MJ, Gunderson LL. Reduced acute bowel toxicity in patients treated with intensity-modulated radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 2012; 82 (05) 1981-1987
    CrossrefPubMedGoogle Scholar
  • 41 Wang L, Li ZY, Li ZW. , et al. Efficacy and safety of neoadjuvant intensity-modulated radiotherapy with concurrent capecitabine for locally advanced rectal cancer. . Dis Colon Rectum 2015; 58 (02) 186-192
    CrossrefPubMedGoogle Scholar
  • 42 Hong TS, Moughan J, Garofalo MC. , et al. NRG Oncology Radiation Therapy Oncology Group 0822: a phase 2 study of preoperative chemoradiation therapy using intensity modulated radiation therapy in combination with capecitabine and oxaliplatin for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2015; 93 (01) 29-36
    CrossrefPubMedGoogle Scholar
  • 43 Ceelen W, Boterberg T, Pattyn P. , et al. Neoadjuvant chemoradiation versus hyperfractionated accelerated radiotherapy in locally advanced rectal cancer. Ann Surg Oncol 2007; 14 (02) 424-431
    CrossrefPubMedGoogle Scholar
  • 44 Coucke PA, Notter M, Stamm B. , et al; All Surgeons From Public Hospitals And Private Clinics. Preoperative hyper-fractionated accelerated radiotherapy (HART) in locally advanced rectal cancer (LARC) immediately followed by surgery. A prospective phase II trial. Radiother Oncol 2006; 79 (01) 52-58
    CrossrefPubMedGoogle Scholar
  • 45 Duncan W, Arnott SJ, Jack WJ, Orr JA, Kerr GR, Williams JR. Results of two randomised clinical trials of neutron therapy in rectal adenocarcinoma. Radiother Oncol 1987; 8 (03) 191-198
    CrossrefPubMedGoogle Scholar
  • 46 Yamada S, Kamada T, Yasuda S. , et al. Phase I/II trial of carbon-ion therapy for patients with locally recurrent rectal cancer. Proc ASCO 2005; 22: 280s
    PubMedGoogle Scholar
  • 47 van der Zee J, González González D, van Rhoon GC, van Dijk JD, van Putten WL, Hart AA. ; Dutch Deep Hyperthermia Group. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Lancet 2000; 355 (9210): 1119-1125
    CrossrefPubMedGoogle Scholar
  • 48 Juffermans JH, Hanssens PE, van Putten WL, van Rhoon GC, van Der Zee J. Reirradiation and hyperthermia in rectal carcinoma: a retrospective study on palliative effect. Cancer 2003; 98 (08) 1759-1766
    CrossrefPubMedGoogle Scholar